文献速递头颈与中枢神经肿瘤

卡瑞利珠单抗联合阿帕替尼治疗复发或转移性鼻咽癌:开放标签、单臂、II期研究

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
PubMed 文献 · J Clin Oncol · 2023-02-03

这项单臂Simon两阶段II期研究纳入58例一线系统治疗失败且未接受过免疫检查点抑制剂的复发/转移性鼻咽癌患者,给予卡瑞利珠单抗200 mg每3周一次联合阿帕替尼250 mg每日一次。客观缓解率为65.5%,疾病控制率为86.2%,中位无进展生存期10.4个月;≥3级治疗相关不良事件发生率为58.6%,鼻咽坏死与局部复发及再程放疗相关。

要点

  • 客观缓解率65.5%(95%CI 51.9-77.5),疾病控制率86.2%(95%CI 74.6-93.9)。
  • 中位无进展生存期10.4个月(95%CI 7.2-13.6),中位随访12.4个月。
  • ≥3级治疗相关不良事件58.6%,常见为高血压19.0%、鼻咽坏死15.5%。

核心结论

  • 卡瑞利珠单抗联合阿帕替尼在经一线治疗失败的难治性复发/转移性鼻咽癌患者中显示出有前景的抗肿瘤活性。
  • 58.6%的患者发生中度至重度治疗相关不良事件,包括与局部复发和再程放疗史相关的鼻咽坏死。

研究设计与样本

  • 单臂、Simon两阶段II期研究,入组对至少一线系统治疗难治且未接受过免疫检查点抑制剂的复发/转移性鼻咽癌患者。
  • 患者接受卡瑞利珠单抗200 mg每3周一次联合阿帕替尼250 mg每日一次。
  • 2020年10月14日至2021年12月23日共入组58例患者,全部纳入疗效和安全性分析集。

主要发现

  • 客观缓解率为65.5%(95%CI 51.9-77.5),疾病控制率为86.2%(95%CI 74.6-93.9)。
  • 中位缓解持续时间未达到,中位无进展生存期为10.4个月(95%CI 7.2-13.6),中位随访时间12.4个月(范围2.1-19.9个月)。
  • 34例(58.6%)患者报告≥3级治疗相关不良事件,最常见为高血压(19.0%)、鼻咽坏死(15.5%)、头痛(12.1%)、AST升高(10.3%)和肌酸磷酸激酶升高(10.3%)。
  • 16例(27.6%)患者在疾病进展前因无法耐受的治疗相关不良事件停用阿帕替尼,最常见并发症为鼻咽坏死(9/16;56.3%)。
  • 复发性鼻咽病灶(比值比5.94 [95%CI 1.45-24.24])和再程放疗(比值比5.33 [95%CI 1.15-24.79])与鼻咽坏死显著正相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC). METHODS: This single-arm, Simon two-stage study enrolled patients with recurrent/metastatic NPC who were refractory to at least first-line systemic therapy and treatment-naive to immune checkpoint inhibitors. The patients received camrelizumab 200 mg once every 3 weeks and apatinib 250 mg once per day. The primary end point was the objective response rate. Key secondary end points included disease control rate, progression-free survival, duration of response, overall survival, and safety. RESULTS: Between October 14, 2020, and December 23, 2021, 58 patients were enrolled, and all were included in the efficacy and safety analysis set. The objective response rate was 65.5% (95% CI, 51.9 to 77.5), and the disease control rate was 86.2% (95% CI, 74.6 to 93.9). The median duration of response was not reached, and the median progression-free survival was 10.4 months (95% CI, 7.2 to 13.6), with a median follow-up duration of 12.4 months (range, 2.1-19.9 months). Treatment-related adverse events (TRAEs) of grade 3 or higher were reported in 34 (58.6%) patients, with the most common being hypertension (19.0%), nasopharyngeal necrosis (15.5%), headache (12.1%), AST elevation (10.3%), and creatine phosphokinase elevation (10.3%). Sixteen (27.6%) patients discontinued apatinib treatment before progression because of unbearable TRAEs, and the most common complication was nasopharyngeal necrosis (9/16; 56.3%). Recurrent nasopharyngeal lesions (odds ratio, 5.94 [95% CI, 1.45 to 24.24]) and reirradiation (odds ratio, 5.33 [95% CI, 1.15 to 24.79]) were significantly positively correlated with nasopharyngeal necrosis. CONCLUSION: Camrelizumab plus apatinib had promising antitumor activity in patients with refractory recurrent/metastatic NPC who failed first-line therapy. Moderate to severe TRAEs were experienced by 58.6%, including nasopharyngeal necrosis associated with local recurrence and a history of reirradiation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ding X, Zhang WJ, You R, et al. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2023. PMID: 36735896. doi:10.1200/JCO.22.01450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。